150 related articles for article (PubMed ID: 35365851)
1. Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
Sorce G; Flammia RS; Hoeh B; Chierigo F; Hohenhorst L; Panunzio A; Stabile A; Gandaglia G; Tian Z; Tilki D; Terrone C; Gallucci M; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Prostate; 2022 Jun; 82(10):1040-1050. PubMed ID: 35365851
[TBL] [Abstract][Full Text] [Related]
2. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients.
Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Anceschi U; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
Int Urol Nephrol; 2022 Oct; 54(10):2521-2528. PubMed ID: 35838831
[TBL] [Abstract][Full Text] [Related]
3. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Becker A; Chun FKH; Karakiewicz PI
Prostate; 2022 May; 82(6):687-694. PubMed ID: 35188982
[TBL] [Abstract][Full Text] [Related]
4. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
5. Improving the Stratification of Patients With Intermediate-risk Prostate Cancer.
Stolzenbach LF; Nocera L; Collà-Ruvolo C; Tian Z; Knipper S; Maurer T; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2021 Apr; 19(2):e120-e128. PubMed ID: 33358891
[TBL] [Abstract][Full Text] [Related]
6. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
[TBL] [Abstract][Full Text] [Related]
7. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
[TBL] [Abstract][Full Text] [Related]
8. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
[TBL] [Abstract][Full Text] [Related]
9. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Urol Oncol; 2022 Sep; 40(9):407.e9-407.e19. PubMed ID: 35817649
[TBL] [Abstract][Full Text] [Related]
11. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
Preisser F; Marchioni M; Nazzani S; Bandini M; Tian Z; Saad F; Pompe RS; Briganti A; Budäus L; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Oncol; 2018 Jun; 1(2):160-168. PubMed ID: 31100241
[TBL] [Abstract][Full Text] [Related]
12. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.
Bakavičius A; Drevinskaitė M; Daniūnaitė K; Barisienė M; Jarmalaitė S; Jankevičius F
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32033148
[No Abstract] [Full Text] [Related]
14. Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.
Schiffmann J; Wenzel P; Salomon G; Budäus L; Schlomm T; Minner S; Wittmer C; Kraft S; Krech T; Steurer S; Sauter G; Beyer B; Boehm K; Tilki D; Michl U; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2015 Jul; 33(7):329.e13-9. PubMed ID: 25960411
[TBL] [Abstract][Full Text] [Related]
15. Advancing Age and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men with Gleason Score 6 Prostate Cancer.
Leeman JE; Chen MH; Huland H; Graefen M; D'Amico AV; Tilki D
Clin Genitourin Cancer; 2019 Dec; 17(6):e1116-e1121. PubMed ID: 31601512
[TBL] [Abstract][Full Text] [Related]
16. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
[TBL] [Abstract][Full Text] [Related]
17. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
[TBL] [Abstract][Full Text] [Related]
18. Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance.
Park HJ; Ha YS; Park SY; Kim YT; Lee TY; Kim JH; Lee DH; Kim WJ; Kim IY
Urol Int; 2013; 90(3):301-5. PubMed ID: 23391718
[TBL] [Abstract][Full Text] [Related]
19. Perineural invasion on biopsy is associated with upstaging at radical prostatectomy in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Morash C; Bateman J; Mai KT; Belanger EC; Robertson SJ; Breau RH
Pathol Int; 2016 Nov; 66(11):629-632. PubMed ID: 27709739
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific Antigen Density Is a Good Predictor of Upstaging and Upgrading, According to the New Grading System: The Keys We Are Seeking May Be Already in Our Pocket.
Brassetti A; Lombardo R; Emiliozzi P; Cardi A; Antonio V; Antonio I; Aldo S; Tommaso R; Alberto P; Gianluca D
Urology; 2018 Jan; 111():129-135. PubMed ID: 29032238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
